Nipocalimab-Aahu
Nipocalimab-aahu is a targeted antibody therapy used to treat generalized myasthenia gravis and warm autoimmune hemolytic anemia in adults and adolescents 12 and older.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Nipocalimab-Aahu: Patient Information Guide
A plain-language walkthrough of Nipocalimab-Aahu — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Nipocalimab-aahu (brand name Imaavy) is approved for two autoimmune conditions in adults and adolescents 12 years of age and older:
- Generalized myasthenia gravis (gMG): Imaavy treats this muscle-weakening disease in patients who test positive for anti-AChR (anti-acetylcholine receptor) or anti-MuSK (anti-muscle-specific tyrosine kinase) antibodies.
- Warm autoimmune hemolytic anemia (wAIHA): Imaavy treats this red blood cell destruction disorder in patients who are currently or have previously been treated with corticosteroids.
⚙️How it works▾
Nipocalimab-aahu is a human monoclonal antibody — a precisely engineered immune protein — that targets and blocks the neonatal Fc receptor (FcRn). This receptor normally acts like a recycling system, pulling IgG antibodies back into circulation to keep their levels up. By blocking FcRn, nipocalimab-aahu disrupts that recycling, causing overall IgG levels to fall — including the specific harmful antibodies driving the disease. In gMG, this means lower levels of the antibodies attacking nerve-muscle junctions; in wAIHA, it means lower levels of the antibodies targeting red blood cells.
💊How it's taken▾
Imaavy is given only as an intravenous (IV) infusion in a clinical setting — never as a pill or at-home injection. For gMG, a higher starting dose is given first, followed by a lower maintenance dose every two weeks. For wAIHA, the same dose level is continued every four weeks after the initial infusion.
- Always arrive for scheduled infusions — if you miss one, get it as soon as possible and then resume your regular interval.
- Vaccines should be reviewed and brought up to date before starting treatment; live vaccines should not be given during treatment.
🤒Side effects — in detail▾
The most commonly reported side effects with Imaavy include:
- Respiratory tract infections (colds, bronchitis, COVID-19, pneumonia) — the most frequent in gMG patients
- Peripheral edema (swelling in the legs or feet)
- Muscle spasms
- Diarrhea
- Fever
- Abdominal pain and back pain
- Dizziness or nausea
- Headache, chills, or rash during or after the infusion
More serious reactions — including severe allergic reactions (anaphylaxis, angioedema), serious infections, and reactivation of dormant viruses like shingles — require immediate medical attention. You will be monitored for at least 30 minutes after every infusion.
⚠️Warnings & precautions▾
- Infections: Imaavy lowers IgG levels, which weakens your body's defense against infections. Serious infections occurred in clinical studies, and dormant viruses like herpes zoster (shingles) and Epstein-Barr virus can reactivate — including one fatal case. Do not start Imaavy during an active infection.
- Severe allergic reactions: Anaphylaxis and angioedema have been reported. Imaavy must not be used by anyone with a prior serious allergic reaction to nipocalimab-aahu or its ingredients.
- Infusion-related reactions: Headache, chills, nausea, rash, and dizziness during or within two days of an infusion have occurred. Severe reactions require stopping the infusion; mild-to-moderate reactions may be managed by slowing the drip and pre-medicating.
- Live vaccines: Because IgG levels are reduced during treatment, live vaccines should not be given while on Imaavy.
- Pregnancy: Animal studies showed placental injury and fetal loss. If you become pregnant during treatment, your healthcare provider should be notified immediately.
🔀What it interacts with▾
Nipocalimab-aahu can affect how other medicines work because it lowers IgG levels throughout the body:
- FcRn-binding medications (such as IVIG — intravenous immunoglobulin — other monoclonal antibody therapies, or medicines containing an IgG antibody component): Imaavy may lower their levels in the blood, reducing how well they work. Your doctor should monitor these medications closely, and may consider switching away from Imaavy if long-term use of the other medication is essential.
- Live vaccines: The immune response to live vaccines is unknown during treatment, and live vaccines are not recommended while taking Imaavy.
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Serious allergy history: Do not use Imaavy if you have had a serious allergic reaction (such as anaphylaxis or angioedema) to nipocalimab-aahu or any ingredient in the product — this is a contraindication.
- Active infection: Imaavy should not be started until any active infection has resolved.
- Vaccines: Make sure age-appropriate vaccines are up to date before starting; live vaccines should not be given during treatment.
- Pregnancy: Limited human data exist; animal studies showed fetal harm including fetal loss. Discuss risks and benefits with your doctor, and report any pregnancy during treatment by contacting Janssen at 1-800-526-7736.
- Breastfeeding: Nipocalimab-aahu has been detected in breast milk; effects on the nursing infant are not fully known. Discuss with your doctor.
- Infants exposed in the womb: Babies born to mothers who received Imaavy during pregnancy may have reduced protective antibodies for 6 months or more; monitor for serious infections and discuss live vaccine timing carefully.
- Children under 12: Safety and effectiveness have not been established in this age group.
- Older adults (65+): Older adults were included in studies, but there is not yet enough data to confirm whether responses differ from younger adults.
📡Pharmacodynamics — effects in the body▾
By blocking the FcRn recycling receptor, nipocalimab-aahu measurably reduces circulating IgG antibodies — including the specific disease-causing ones. In gMG studies, treatment with Imaavy led to reductions in both anti-AChR and anti-MuSK autoantibodies compared to pre-treatment levels, with similar reductions seen in adolescents and adults. In wAIHA studies, it reduced total IgG and the anti-red blood cell IgG autoantibodies that drive red blood cell destruction.
🔬Pharmacokinetics — how your body processes it▾
Nipocalimab-aahu behaves in a concentration-dependent way in the body — as more drug is present, it clears more slowly, which is described as nonlinear pharmacokinetics. It is distributed in a relatively small volume (staying mostly in the bloodstream and nearby fluids) and is broken down by the body's natural protein-digesting enzymes into small peptides and amino acids. The drug's half-life (the time for blood levels to fall by half) is approximately 29 hours after a single dose, and age, sex, and race do not meaningfully affect how the body handles it. Steady-state blood levels in adolescents 12–16 are comparable to those in adults.
📦How to store it▾
Store vials refrigerated at 2 ºC to 8 ºC (36 ºF to 46 ºF) in the original carton to protect from light until the time of use. Do not freeze. of the diluted IMAAVY solution, see Dosage and Administration (2.
📄 Written from Nipocalimab-Aahu’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Nipocalimab-Aahu — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly is Imaavy used for? ▾
How is this medication given? Can I take it at home? ▾
What side effects should I watch out for? ▾
Does this medication increase my chances of getting sick? ▾
Are there any vaccines I should get before starting — or avoid while on it? ▾
Is it safe to take Imaavy if I'm pregnant or breastfeeding? ▾
Is Nipocalimab-Aahu available over the counter? ▾
When was Nipocalimab-Aahu first available? ▾
💬 Answers drafted from Nipocalimab-Aahu’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Nipocalimab-Aahu comes
Nipocalimab-Aahu is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Imaavy intravenous infusion is used to treat generalized myasthenia gravis (gMG) in adults and adolescents 12 and older who are AChR or MuSK antibody positive
- Imaavy intravenous infusion is used to treat warm autoimmune hemolytic anemia (wAIHA) in adults and adolescents 12 and older who are currently or previously treated with corticosteroids
- Imaavy must be diluted with 0.9% Sodium Chloride (normal saline) before administration and given only by intravenous infusion
- Imaavy is administered through an infusion set with a 0.2-micron in-line filter; it should not be mixed in the same IV line with other medications
- Patients should be monitored during the infusion and for 30 minutes afterward for signs of allergic or infusion-related reactions
- If a scheduled Imaavy infusion is missed, it should be given as soon as possible and then resumed on the regular schedule
📊 Nipocalimab-Aahu across the U.S. market
How Nipocalimab-Aahu appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
📈 How widely Nipocalimab-Aahu is used
A general measure of how commonly Nipocalimab-Aahu is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q3–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Nipocalimab-Aahu is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Nipocalimab-Aahu prescribed? Of the 1,596 medications we measure, Nipocalimab-Aahu ranks #1,580 by Medicaid prescriptions — more than 1% of them.
Utilization by Nipocalimab-Aahu product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
6.5 ML nipocalimab-aahu 185 MG/ML Injection
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2712708
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Nipocalimab-Aahu, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 1 of 1 listed Nipocalimab-Aahu NDCs with Medicaid activity.
🔍 Compare Nipocalimab-Aahu products
A representative set of FDA-listed product records for Nipocalimab-Aahu — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 185 mg/mL | Intravenous | Janssen Biotech, Inc. × 4 listings | BLA | View NDC → |
Showing 4 of 4 products — FDA National Drug Code Directory. See every product, package size and price: browse all 4 Nipocalimab-Aahu NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Nipocalimab-Aahu — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Nipocalimab-Aahu in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Nipocalimab-Aahu went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 2712693 1 dose form · 2 strengths
-
Dose form (SCDF) Injection RxCUI 2712696In current FDA listingsClinical drug / strength (SCD) 1.62 ML nipocalimab-aahu 185 MG/MLRxCUI 27126996.5 ML nipocalimab-aahu 185 MG/MLRxCUI 2712708
Look up RxCUI 2712693 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Nipocalimab-Aahu is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Nipocalimab-Aahu belongs to the Neonatal fragment crystallizable receptor (FcRn) inhibitors class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 1 FDA-filed SPL label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Janssen Biotech, Inc. is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.